Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.77 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.77 |
| ▸ | F2 | P00734 | 3/20 | 0.77 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.77 |
| ▸ | PLG | P00747 | 1/20 | 0.77 |
| ▸ | PLAU | P00749 | 1/20 | 0.77 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.77 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.77 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.75 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.75 |
| ▸ | F7 | P08709 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4322200 | 0.98 | TPSAB1 (0.78) | F10TPSAB1F2PRSS1PLG | |
| SCHEMBL6163820 | 0.93 | F10 (0.85) | F10TPSAB1F2PRSS1PLG | |
| SCHEMBL7406105 | 0.93 | F10 (0.68) | F10TPSAB1F2PRSS1PLG | |
| SCHEMBL7406681 | 0.93 | F10 (0.68) | F10TPSAB1F2PRSS1PLG | |
| SCHEMBL7406863 | 0.92 | F10 (0.76) | F10TPSAB1F2PRSS1PLG | |
| Hydrochloric Acid SCHEMBL28579078 | 0.92 | F10 (0.82) | F10TPSAB1F2PRSS1PLG | |
| SCHEMBL7406430 | 0.92 | F10 (0.76) | F10TPSAB1F2PRSS1PLG | |
| SCHEMBL7409221 | 0.92 | F10 (0.66) | F10TPSAB1F2PRSS1PLG | |
| SCHEMBL7400515 | 0.92 | F10 (0.67) | F10TPSAB1F2PRSS1PLG | |
| Hydrochloric Acid SCHEMBL30386514 | 0.92 | F10 (0.82) | F10TPSAB1F2PRSS1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949474-B2 | Methods and reagents for maintaining the viability of cancer cells in surgically removed tissue | TRUCKEE APPLIED GENOMICS, LLC (US) | 2018-04-24 | — | — | US | claimed |
| US-9445586-B2 | Methods and reagents for maintaining the viability of cancer cells in surgically removed tissue | TRUCKEE APPLIED GENOMICS, LLC (US) | 2016-09-20 | — | — | US | claimed |
| US-20160235055-A1 | METHODS AND REAGENTS FOR MAINTAINING THE VIABILITY OF CANCER CELLS IN SURGICALLY REMOVED TISSUE | TRUCKEE APPLIED GENOMICS, LLC | 2016-08-18 | — | — | US | claimed |
| EP-1727551-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LTD (GB) | 2009-09-09 | — | — | EP | claimed |
| US-7569342-B2 | Removal of molecular assay interferences | SIERRA MOLECULAR CORP. (US) | 2009-08-04 | — | — | US | claimed |
| EP-1727550-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LTD (GB) | 2009-07-29 | — | — | EP | claimed |
| EP-2076595-A2 | REMOVAL OF MOLECULAR ASSAY INTERFERENCES FOR NUCLEIC ACIDS EMPLOYING BUFFERED SOLUTIONS OF CHAOTROPES | Sierra Molecular Corporation (US) | 2009-07-08 | — | — | EP | claimed |
| US-20080171691-A1 | Inhibition of invasive remodelling | LUND LEIF ROGE | 2008-07-17 | — | — | US | claimed |
| US-20080124728-A1 | Removal of Molecular Assay Interferences for Nucleic Acids Employing Buffered Solutions of Chaotropes | SIERRA MOLECULAR CORPORATION | 2008-05-29 | — | — | US | claimed |
| WO-2008033936-A2 | REMOVAL OF MOLECULAR ASSAY INTERFERENCES FOR NUCLEIC ACIDS EMPLOYING BUFFERED SOLUTIONS OF CHAOTROPES | SIERRA MOLECULAR CORPORATION (US) | 2008-03-20 | — | — | WO | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004006842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| US-6583149-B1 | 2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-Dioxolane | BIOCHEM PHARMA INC. (CA) | 2003-06-24 | — | — | US | claimed |
| US-20020102580-A1 | Removal of molecular assay interferences | SIERRA MOLECULAR CORP. | 2002-08-01 | — | — | US | claimed |
| US-20020099004-A1 | Inhibition of invasive remodelling | LUND LEIF ROGE (DK) | 2002-07-25 | — | — | US | claimed |
| EP-0942746-A1 | INHIBITION OF INVASIVE REMODELLING | FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING (DK) | 1999-09-22 | — | — | EP | claimed |
| WO-1998024474-A1 | INHIBITION OF INVASIVE REMODELLING | FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING (DK) | 1998-06-11 | — | — | WO | claimed |
| US-4940723-A | Use of bis-(5-amidino-2-benzimidazolyl) methane (BABIM) to treat arthritis | UNIVERSITY OF NORTH CAROLINA, CHAPEL HILL (US) | 1990-07-10 | — | — | US | claimed |
| US-4324794-A | PREVENTION OF EPIDEMICS BY PROPHYLACTIC ADMINISTRATION | RESEARCH TRIANGLE INSTITUTE (US) | 1982-04-13 | — | — | US | claimed |